



RECORDATI S.p.A.

HEADQUARTER

Via Matteo Civitali, 1  
20148 Milan, Italy  
Ph. +39 02 48 787.1  
www.recordati.com

# CORPORATE BROCHURE





# AT THE FOREFRONT OF LIFE-ENHANCING AND LIFE-CHANGING MEDICINES FOR ALMOST 100 YEARS

With its beginnings in a family run pharmacy in Correggio, Italy in the 1920s, Recordati is now a global pharmaceutical group, listed on the Italian Stock Exchange, with over 4,300 employees.

We are a group of like-minded, passionate individuals who go to extraordinary lengths for our partners, customers, investors, and the people across the globe we serve.

We develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest.

At Recordati, our mantra is simple. We've always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether that is for common diseases or the rarest – we want to give people the opportunity to be the best version of themselves.

This drive will never stop. Together, we will always be reimagining tomorrow – with new ideas, new technologies and new innovations to fight diseases.

**Recordati. Unlocking the full potential of life.**



# THE MILESTONES OF A LONG SUCCESS STORY



- 1926** Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)
- 1927** Launch of Antispasmina Colica®, gastrointestinal tract antispasmodic
- 1953** Transfer of the headquarters to Milan
- 1961** Recordati - Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones
- 1963** Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia
- 1973** Launch of Urispas® (flavoxate), a urinary antispasmodic. Synthesized and developed by Recordati, it was the first Italian drug to receive FDA approval in the US



- 1995** Beginning of the process of internationalisation
- 1997** Establishment of a subsidiary in Spain
- 1997** Launch of Zanidip® (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati
- 1999** Acquisition of Doms Adrian (France)
- 2000** Acquisition of Bouchara (France)
- 2001** Establishment of Bouchara Recordati in France
- 2005** Acquisition of Merckle Recordati in Germany
- Establishment of Recordati in the United Kingdom
- Establishment of Recordati in Greece
- Establishment of the new pharmaceutical chemical plant in Cork, Ireland
- 2006** Acquisition of the Grupo Jaba companies in Portugal



- 2012** Entry into the US market - Rare Diseases sector
- Acquisition of a product portfolio for the treatment of a number of Rare Diseases in the US
- Acquisition of Farma-Projekt in Poland
- 2013** Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia
- Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain
- 2014** US Food and Drug Administration (FDA) granted Orphan Drug Designation for the use of Carbaglu® in the treatment of organic acidemias
- 2015** Establishment of new subsidiaries in Brazil, Mexico and Colombia
- Carbaglu® authorized for sale in Canada for the treatment of NAGS deficiency



- 2019** Expansion of the Rare Diseases product portfolio: entry into the endocrinology sector
- Licence agreement in Japan for Juxtapid® (lomitapide), a treatment for the homozygous familial hypercholesterolemia (HoFH)
- Acquisition of worldwide rights to Signifor® (pasireotide) and Signifor® LAR® for the treatment of Cushing's disease and Acromegaly and to Isturisa® (osilodrostat) for the treatment of endogenous Cushing's syndrome in Europe
- 2020** Establishment of Recordati Bulgaria
- Marketing authorization of Cystadrops® 0.37% (cysteamine-based ophthalmic solution), for the treatment of Cystinosis patients in the USA
- Launch of Isturisa® in US, France and Germany, orphan pharmaceutical product approved by the European Commission and the Food and Drug Administration (FDA)
- Direct marketing of Signifor® and Signifor® LAR in the US
- Licence agreement with ARS Pharmaceuticals for ARS-1, epinephrine-based nasal spray

**1926**  
Recordati was established

**1984**  
Listing on the Italian Stock Exchange

**1995**  
Beginning of the process of internationalisation

**2007**  
Entry into the Rare Diseases sector

**2012**  
Entry into the US market Rare Diseases sector

**2016**  
SPC and CHC portfolio strengthening


**2019**  
Entry into the endocrinology sector Rare Diseases

**2021-23**  
Entry into niche oncology Rare Diseases

- 1984** Listing on the Italian Stock Exchange
- 1986** Launch of Lomexin® (fenticonazole), a dermatological and gynecological anti-mycotic born in the Recordati research laboratories



- 2007** Entry into the Rare Diseases sector
- Acquisition of Orphan Europe, now Recordati Rare Diseases
- Launch of Zanipress® (lercanidipine + enalapril), antihypertensive developed by Recordati
- 2008** Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
- Acquisition of Yeni İlaç in Türkiye
- 2009** Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia
- 2010** Launch of Urorec® (silodosin), an alpha blocker prescribed for the benign prostatic hyperplasia (BPH) treatment
- Carbaglu® (carglumic acid) approved by the Food and Drug Administration (FDA) in the US for the treatment of NAGS deficiency
- Acquisition of ArtMed International in Romania, now Recordati Romania
- 2011** Extension of the indications for use of Carbaglu® in Europe
- Acquisition of Dr. F. Frik İlaç in Türkiye
- Launch of Livazo® - Alipza® (pitavastatina) for hypercholesterolemia in Europe
- Acquisition of Procto-Glyvenol®, a product prescribed for the treatment of haemorrhoids



- 2016** SPC and CHC portfolio strengthening
- Acquisition of Italchimici in Italy
- Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
- Agreement with Assistance Publique - Hopitaux de Paris for the development of a product for the treatment of Maple Syrup Urine Disease (MSUD)
- Licence agreement with Gedeon Richter for the commercialisation of Reagila® (cariprazine) for the treatment of schizophrenia
- 2017** European marketing authorization of Cystadrops® (cysteamine hydrochloride), eye drops for the local treatment of Cystinosis
- Acquisition of Seloken®/Seloken® ZOK (metoprolol succinate) and Logimax® (metoprolol succinate and felodipine) for a range of heart diseases
- Licence agreement with MimeTech for the development of a drug for the treatment of neurotrophic keratitis
- 2018** Acquisition of Cystagon® (cysteamine bitartrate) for the proven nephropathic Cystinosis
- Acquisition of Natural Point in Italy
- Exclusive licence agreement for the marketing of Ledaga® (chlormethine hydrochloride) for the topical treatment of mycosis fungoides
- Ledaga® is granted Orphan Drug Designation in Europe
- Acquisition of Tonipharm in France
- Launch of Reagila® (cariprazine) in Europe
- Establishment of new subsidiaries in Japan and Australia

- 2021-23** Expansion of the Rare Disease product portfolio: entry into niche oncology
- Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on Rare Diseases and niche oncology
- Licence agreement and distribution of Eligard® (leuprorelin acetate), for the treatment of hormone-dependent prostate cancer in Europe, Türkiye, Russia and other countries
- Direct marketing of Eligard®
- New indication for Carbaglu® 200 mg tablets approved by the FDA in the US
- Acquisition of Flatoril® (clebopride plus simethicone) in Spain, for gastrointestinal disorders
- Launch of Isturisa® in Japan following approval by MHLW
- Establishment of a new subsidiary in China
- Agreement with GSK to commercialise Avodart® (dutasteride) and Combodart®/Duodart® (dutasteride/tamsulosin)
- Carbaglu® receives marketing authorization in China

- LEGEND**
- Recordati
  - Specialty & Primary Care products (SPC)
  - Rare Disease products
  - SPC acquisition, new companies and plants
  - Rare Diseases acquisition, new companies and plants
  - Licencing and commercial agreements







## TABLE OF CONTENTS

<b>01. RECORDATI: TODAY AND THE FUTURE</b>	<b>7</b>
<b>02. RECORDATI'S KEY FIGURES</b>	<b>12</b>
<b>03. THE RECORDATI SHARE</b>	<b>15</b>
<b>04. RECORDATI IN THE WORLD</b>	<b>18</b>
<b>05. SUCCESSFUL ACTIVITIES AND PRODUCTS</b>	<b>21</b>
• Specialty & Primary Care	
• Rare Diseases	
• Pharmaceutical chemicals	
<b>06. PHARMACEUTICAL PRODUCTION</b>	<b>32</b>
<b>07. RESEARCH AND INNOVATION AT RECORDATI</b>	<b>38</b>
<b>08. PARTNERING WITH THE RECORDATI GROUP</b>	<b>41</b>
<b>09. SUSTAINABILITY</b>	<b>46</b>
• The Sustainability Plan	
• Support for local communities	
• The International Prize for Scientific Research Arrigo Recordati	



# CONTINUING OUR GROWTH JOURNEY

SPECIALTY & PRIMARY CARE  
2022 REVENUES

**1,257.5**

Million Euros  
(67.8%)

RARE DISEASES  
2022 REVENUES

**595.8**

Million Euros  
(32.2%)

## 01. RECORDATI: TODAY AND THE FUTURE

**WE ARE CONTINUALLY GROWING,  
WITH A FOCUS ON DEVELOPING  
NEW SPECIALTIES, NEW  
TREATMENTS AND INVESTING  
IN MEDICAL INNOVATIONS THAT  
BRING A BRIGHTER FUTURE TO  
PATIENTS ACROSS THE WORLD.**

We are uniquely structured to bring treatment options across Specialty & Primary Care, consumer healthcare, and Rare Diseases.

- We have fully-integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
- We promote well-being.
- We have a diversified portfolio operating in around 150 countries worldwide.
- We are a partner of choice due to our unique structure.
- We maintain the highest quality and safety standards of our products throughout all their life cycle.
- We manufacture pharmaceutical ingredients to support our supply-chain, whilst also providing to customers worldwide.



We are based in Milan, Italy and have been listed on the Italian Stock Exchange since 1984.

We produce and promote a wide range of innovative products in around 150 countries.

We market a number of specialties generated by our original research.

Our portfolio includes both products for Specialty & Primary Care and treatments for Rare Diseases.





## SPECIALTY & PRIMARY CARE



We have a strong and proven heritage of supporting people living with a wide range of common illnesses that affect large populations day-to-day.

We create value for patients, payers, and physicians across Specialty & Primary Care with both prescription and self-medication treatments, with a focus on cardiovascular, urological and gastrointestinal areas.

We provide treatments globally, with direct presence in Europe and North Africa and have proven experience in supporting access to medicines throughout their lifecycle.

## RARE DISEASES



Of the 7,000 known Rare Diseases, less than 10% have an available treatment option. Since 2007, through our dedicated business unit Recordati Rare Diseases, we've focused on helping the few who suffer from little known conditions.

Our mission is to reduce the impact of rare and devastating diseases by providing urgently needed medicines in key therapeutic areas including:

- Metabolic.
- Endocrinology.
- Oncology.

## PHARMACEUTICAL CHEMICALS

We produce various active and intermediate ingredients which, in addition to meeting our own needs, we also sell to third-party pharmaceutical companies.

# RECORDATI'S JOURNEY INTO THE FUTURE

**THE PROVEN ABILITY FOR CREATING PROFITABLE PARTNERSHIPS WITH IMPORTANT PLAYERS IN THE PHARMACEUTICAL SECTOR WILL CONTINUE TO SUPPORT US IN OUR QUEST TO IDENTIFY NEW OPPORTUNITIES AND FINALIZE NEW LICENCE AGREEMENTS FOR THE DEVELOPMENT OF HIGH VALUE MEDICINAL PRODUCTS.**

## A WIDE AND DIFFUSED PRESENCE


With operations in all European countries, in Russia and in the C.I.S. countries, in Ukraine, Türkiye and North Africa, in the United States, Canada, Latin America, Japan, Australia and China, we continue to strengthen our geographical presence.

We continue to increase our activities in Europe with a new long-term commercialisation agreement with GSK in 2023 for Avodart® (dutasteride) and Combodart®/Duodart® (dutasteride/tamsulosin), whilst continuing to make our products for the treatment of Rare Diseases available worldwide, including in the United States (largest market) Canada, Latin America, Japan, China and the Asia-Pacific regions.



## M&A AND BUSINESS DEVELOPMENT

An integral part of the Recordati history



## A STRONGER PRODUCT PORTFOLIO

The launch of innovative new products, the enhancement of our product portfolio with specialties from our own research and development or from targeted licence agreements or specific acquisitions, will boost our Group's growth.

## A CONSTANT INVESTMENT IN RESEARCH AND INNOVATION

We are committed to the innovation and marketing of high value-added products. We continuously develop new medicines and believe research and development is a fundamental basis for our growth. Dedication and scientific rigor are always behind our

specialties and self-medication products, which are also produced with the highest levels of quality and safety.

## A STRATEGIC PARTNER

We are an ideal partner for the development and marketing of new products in our markets thanks to:

- Our extensive geographical coverage.
- An efficient in-company network of medical representatives and orphan drug specialists.
- Our significant competence in handling regulatory processes.
- Our profound know-how in the handling of highly specialized products.







# 2022, A YEAR OF STRONG PERFORMANCE

 **REVENUE**  
**1,853.3**  
Million Euros

 **EBITDA**  
**672.8**  
Million Euros


 **ADJ. NET INCOME**  
**473.3**  
Million Euros




# 02. RECORDATI'S KEY FIGURES

2022 was once again a year of strong performance. A number of new initiatives were pursued for the our future development.


## REVENUE




## EBITDA\*




## EBITDA\* AS % OF REVENUE




## RESEARCH AND DEVELOPMENT




## NET INCOME




## ADJUSTED NET INCOME\*\*




## DIVIDEND PER SHARE




## NET INCOME PER SHARE




## ADJUSTED NET INCOME PER SHARE



## PHARMACEUTICAL SALES BY THERAPEUTIC AREA




## GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES



## BALANCE SHEET

31st December 2022



\* Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory according to IFRS 3.

\*\* Net income excluding the amortization and write-down of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.

\*\*\* Pro-forma, not reported in relevant year financial accounts.






# LISTED ON THE ITALIAN STOCK EXCHANGE SINCE 1984

## 03. THE RECORDATI SHARE




### DIVIDEND

(Euro per Share)



### PRINCIPAL SHAREHOLDERS

31st December 2022



### THE RECORDATI SHARE 31st December 2022

<b>Listing</b>	Borsa Italiana, Blue Chip segment, healthcare
<b>ISIN Code</b>	It 0003828271
<b>Ticker</b>	Bloomberg REC IM, Reuters RECI.MI
<b>Index</b>	FTSE MIB, FTSE Italia All-Share Health Care Index, FTSE Italia All-Share Pharmaceuticals & Biotechnology Index, FTSE4Good Index Series, STOXX Europe 600, Euro STOXX Health Care, MSCI Indexes
<b>Share Capital</b>	n. 209,125,156 common shares
<b>Nominal value</b>	€ 0.125 per share
<b>EPS (diluted)</b>	€ 1.494
<b>Dividend per share</b>	€ 1.15





# HEADQUARTERS IN MILAN, ACTIVITIES WORLDWIDE



EMPLOYEES

> **4,300**



MARKETS


~**150**



# 04. RECORDATI IN THE WORLD


We are present in around 150 countries with our Specialty & Primary Care products and our treatments for Rare Diseases.

## SPECIALTY & PRIMARY CARE




- Subsidiaries and direct selling organizations
- Countries where Recordati products are sold (under licence or export)

## GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES IN 2022



## RARE DISEASES



- Subsidiaries and direct presence of orphan drug representatives
- Commercial agreements and direct delivery

## GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES IN 2022








**A TOTAL COMMITMENT**

## 05. SUCCESSFUL ACTIVITIES AND PRODUCTS

Always committed to giving people the opportunity to unlock the full potential of life, we offer a number of innovative and high value-adding pharmaceutical products that constitute a large and qualified product portfolio.

### BREAKDOWN OF REVENUE 2022

**32.2%** RARE DISEASES      **67.8%** SPECIALTY & PRIMARY CARE





## SPECIALTY & PRIMARY CARE

WE MAKE NUMEROUS MEDICINES IN VARIOUS THERAPEUTIC AREAS IN EUROPE AND NORTH AFRICA.



### PRESCRIPTION DRUGS

- We boast an important presence and offer new treatments in the areas of cardiovascular, urological and gastrointestinal diseases.
- We market products developed from our own research and by specific licence agreements that promote a wide range of innovative drugs.

### SELF-MEDICATION PRODUCTS

We are present in this market segment with several established brands, successful products, a wide and updated mix. Constantly seeking new treatments, we offer:

- Consumer healthcare products.
- Food supplements.
- Medical devices.

All our pharmaceutical specialties and self-medication products are characterised by high levels of quality and safety in all countries.

### MAIN PRESCRIPTION PRODUCTS

#### CARDIOVASCULAR

ZANIDIP®/CORIFEO®/LERCADIP®  
(lercanidipine)  
Antihypertensive

ZANIPRESS®/ZANEXTRA®/LERCAPREL®/  
LERCARIL® (lercanidipine + enalapril)  
Antihypertensive

SELOKEN®/SELOKEN®ZOK/BETALOK®ZOK  
(metoprolol succinate)  
Angina pectoris, disturbances of cardiac rhythm, hypertension

LOGIMAX®  
(metoprolol succinate + felodipine)  
Antihypertensive

LOPRESOR® (metoprolol)  
Antihypertensive

LIVAZO®/ALIPZA® (pitavastatin)  
Hypercholesterolaemia

#### UROLOGY AND URO-ONCOLOGY

ELIGARD® (leuprorelin acetate)  
Hormone dependent advanced prostate cancer

AVODART® (dutasteride)  
Benign prostatic hyperplasia (BPH)

COMBODART®/DUODART®  
(dutasteride/tamsulosin)  
Benign prostatic hyperplasia (BPH)

UROREC®/SILODYX® (silodosin)  
Benign prostatic hyperplasia

URISPAS®/GENURIN® (flavoxate)  
Urinary tract muscle relaxant

VITAROS®/VIRIREC® (alprostadil)  
Erectile dysfunction

### MAIN PRESCRIPTION PRODUCTS

FORTACIN® (lidocaine+prilocaine)  
Premature ejaculation

TELEFIL® (tadalafil)  
Benign prostatic hyperplasia (BPH)

#### GASTROENTEROLOGY

CITRAFLEET® (citric acid) and PHOSPHOSODA®  
(sodium dihydrogen phosphate dihydrate)  
Bowel evacuants

CASENLAX® (macrogol) and FLEET ENEMA®  
(monobasic sodium phosphate)  
Constipation and bowel cleansing

#### COUGH & COLD

AIRCORT® (budesonide)  
Asthma

POLYDEXA® (neomycin sulfate)  
Treatment of ear infections

ISOFRA® (framycetin sulfate)  
Treatment of nose and throat infections

#### OTHER

REAGILA® (cariprazine)  
Antipsychotic

TERGYNAN® (metronidazole)  
Gynecological infections

LOMEXIN®/FALVIN® (fenticonazole)  
Antimycotic

GYNOXIN® (fenticonazole nitrate)  
Antimycotic

### MAIN CONSUMER HEALTHCARE PRODUCTS

PROCTO-GLYVENOL® (tribenoside)  
Haemorrhoids

CASENBIOTIC®, REUFLO®R®, BIORALSUERO®,  
REUTERI®, GASTRUS®  
(lactobacillus reuteri protectis)  
Food supplements

MAGNESIO SUPREMO®  
(magnesium carbonate)  
Food supplement

GINKOR® (ginkgo biloba)  
Food supplement


HEXA® LINE OF PRODUCTS (biclotymol)  
Antibacterial for infections of the oral cavity

PROCTOLYN® (fluocinolone  
acetone+ketocaine hydrochloride)  
Haemorrhoids

ALOVEX® LINE OF PRODUCTS (aciclovir)  
Aphthas and mouth sores

EUMILL® (camomilla+hamamelis+euphrasia)  
Vitamin supplement

LACDIGEST® (tilactase)  
Lactose intolerance





## LOCAL PRODUCTS

We market some products locally or product lines through our subsidiaries that maintain prominent positions in their markets of reference.

### ITALY

In Italy, we are committed to the development and commercialisation of ethical products as well as self-medication and food supplement products.

With regards to ethical products, in addition to our consolidated presence in the cardiometabolic area, we offer a unique and complete portfolio for the treatment of urological diseases (BPH, prostate cancer, sexual dysfunction), innovative treatments for respiratory and allergic diseases with a specific focus on pediatric patients, as well as treatments in the gastrointestinal and analgesia areas.

With regards to self-medication products, the successful commercialisation of Eumill® with the newly launched Eumill® Allergy, was a highlight in 2022. For food supplements, Magnesio Supremo® represents a successful example of company innovative activity aiming to offer a wide range of products for consumer needs. In addition Reuflor®, probiotic leader in pediatric area, is evolving with an extension line launch supporting microbiota health for adults.

### FRANCE

Recordati is a prominent name in the French market, known for its diverse range of prescription products targeting key therapeutic areas such as cardiology, uro-oncology, and addiction. Additionally, our self-medication line, which emphasises cough/cold treatments and venotonics, solidifies our market standing.



### GERMANY

Recordati is well-established in Germany with a strong and growing presence in key therapeutic areas such as uro-oncology, orthopedics and CNS.

In addition to our prescription brands and medical devices, our portfolio contains well-known over-the-counter or self medication brands that offer solutions for cough/cold treatment, skin protection and sleeping disorders.

As an organisation, our team is highly motivated to provide best in class education and services to health care professionals and continues healthy organisational development to build on our historic footprint.

### RUSSIA, OTHER C.I.S. COUNTRIES AND UKRAINE

Our operations in Russia, Ukraine, the other C.I.S. markets and the Central Asia, successfully market products indicated for otorhinolaryngological and vaginal infections and boast a leading position in their markets.

### SPAIN

Recordati in Spain has an extensive and substantial portfolio of products, in the area of gastroenterology where our products for bowel cleansing and oral rehydration are undisputed market leaders.

### TÜRKIYE

Recordati markets a diversified product portfolio, well appreciated by practitioners, in the fields of urology, cardiology, gynecology and in physical medicine and rehabilitation.

### NORTH AFRICA

In North Africa and in Tunisia, we are one of the largest local pharmaceutical companies marketing branded generic drugs with leading products in dermatology and in the gastrointestinal and respiratory therapeutic areas.

### OTHER COUNTRIES

We have strengthened our presence in Switzerland with headquarters in Zug and operations also in Austria, Sweden, Denmark, Norway, Finland, Iceland, Benelux, Bulgaria, Poland and in the Baltic States.





## RARE DISEASES

**WE OPERATE IN THE RARE DISEASES SEGMENT WORLDWIDE THROUGH RECORDATI RARE DISEASES.**



We research, develop, produce and market drugs for the treatment of a number of Rare Diseases. These are marketed directly in Europe, the Middle East, United States, Canada, Russia, Australia, Japan, China and in some Latin American countries, and through selected partners in a number of other countries, covering more than 100 countries worldwide.

Highly-trained specialists and scientific support teams collaborate constantly with researchers, medical practitioners and health care professionals, with patient groups and families and with regulators to treat and improve the quality of life of people suffering from these diseases worldwide.

Thanks to a unique distribution system and to specialists dedicated to the promotion and distribution of these products, we are able to reach patients in their home countries.

More than  
**100 COUNTRIES**  
worldwide (direct and indirect sales)

### METABOLIC

Metabolic diseases can be caused by several genetic defects, causing abnormal accumulation of metabolites and/or defect in others. These inborn errors of metabolism affect neonates, children and adults. Since it was founded, Recordati Rare Diseases has been focussing on rare metabolic conditions, many of which can be difficult to diagnose and can be life-threatening.

### ENDOCRINOLOGY

Your endocrine system is comprised of a network of glands in your body that produces and secretes hormones. Hormones are chemical messengers that carry information and instructions from one part of the body to another, that control or regulate many bodily functions, including growth and development, metabolism, reproduction, and mood, among others.

Many diseases may impact how the varied endocrine glands work in the body, resulting in disordered hormone production and secretion, which may underlie burdensome, and in some cases, life-threatening syndromes and conditions if left untreated. Some of these diseases are rare and only affect a few people globally. These conditions are often difficult to diagnose due to lack of awareness of varied signs and symptoms, which can result in delayed diagnosis and/or undertreatment.

Recordati Rare Disease is focused on targeting endocrine conditions associated with high unmet need and burden, and is committed to providing better treatment options and solutions for patients, with a particular focus on improving the lives of those suffering from pituitary and adrenal gland dysfunctions or related conditions, which can impact growth and metabolism imbalances.

### ONCOLOGY

The human body is made up of trillions of cells. When these cells become old or damaged, they die, and need to be replaced with new ones.

Normally, human cells grow and multiply through cell division to create these new cells as they are needed. This cell division and cell growth is self-regulated and self-



#ThisCushing is a global initiative developed by Recordati Rare Diseases in collaboration with an award-winning photographer and internationally-recognised experts in the field of pituitary endocrinological diseases.

[thisiscushing.com](http://thisiscushing.com)





limited in normal conditions. Sometimes, however, this process doesn't happen as it should – and abnormal or damaged cells (so called mutated cancer cells) can grow where they shouldn't, sometimes forming harmful cancerous tumours.

Cancerous tumours can start anywhere and spread to other parts of the body; these are called malignant tumours. Tumours can also

be benign, meaning they grow but they don't spread through the body and tend not to create problems. Recordati Rare Diseases focuses on some of the rarest cancers, in both adult and pediatric indications, where very few treatment options exist.

## MAIN DRUGS FOR THE TREATMENT OF RARE DISEASES

### METABOLIC AND DERMATO-ONCOLOGY

#### CARBAGLU® (carglumic acid)

Treatment of hyperammonemia due to N-Acetylglutamate Synthase deficiency (NAGS deficiency) and some organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia)

#### NORMOSANG®/PANHEMATIN® (human hemin)

Treatment of acute attacks of hepatic porphyria

#### CYSTADROPS® (cysteamine hydrochloride)

Treatment of the ocular manifestations of Cystinosis

#### CYSTAGON® (cysteamine bitartrate)

Treatment of nephropathic Cystinosis

#### CYSTADANE® (betaine anhydrous)

Treatment of homocystinuria

#### LEDAGA® (chlormethine hydrochloride)

Treatment of Mycosis Fungoides (MF), T-Cell Cutaneous Lymphoma (CTCL)

#### JUXTAPID® (lomitapide)

Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

#### COSMEGEN® (dactinomycin for injection)

Treatment of rare cancers: Wilms tumour, infantile rhabdomyosarcoma, Ewing sarcoma and metastatic nonseminomatous testicular cancer

#### PEDEA®/NEOPROFEN® (ibuprofene IV)

Treatment of Patent Ductus Arteriosus (PDA)

### ENDOCRINOLOGY

#### ISTURISA® (osilodrostat)

Treatment of Cushing's disease (United States) and Cushing's syndrome (European Union, Switzerland)

#### SIGNIFOR® e SIGNIFOR® LAR (pasireotide)

Treatment of Cushing's disease and Acromegaly

### ONCOLOGY

#### QARZIBA® (dinutuximab beta, anti-GD2 monoclonal antibody)

Treatment of high-risk neuroblastoma patients aged 12 months and above, who achieved at least a partial response at the chemotherapeutic induction, followed by myeloablative therapy and stem cell transplantation

#### SYLVANT®

(siltuximab, anti-IL-6 monoclonal antibody)

Treatment of idiopathic Multicentric Castleman's Disease (iMCD) in adults

#### FOTIVDA® (tivozanib, oral highly selective small molecule Tyrosine Kinase Inhibitor (TKI) of Vascular Endothelial Growth Factor (VEGF) receptors 1, 2 and 3)

Treatment of first-line of advanced renal cell carcinoma

#### CAPHOSOL® (supersaturated calcium phosphate rinse)

Medical device on prescription for the treatment of oral mucositis due to chemo and radio therapy

## INTERNATIONAL AWARDS

We established track record in the field of orphan drug development. The establishment of scientific networks and engaging with patient organisations together with our efforts to reduce the impact of disease on the lives of patients are the reasons that have contributed to winning of prestigious international awards and that push us to continue in this direction every day.



Our commitment to making our products available to patients suffering from Rare Diseases was recognised by the National Organization for Rare Disorders (NORD) in the United States with its "Corporate Award".

This important award was granted in 2011 in recognition of the introduction into the United States of Carbaglu®, the first specific treatment approved by the FDA (Food and Drug Administration) for NAGS deficiency, a very rare inherited metabolic disease.



The results obtained in improving the diagnosis and management of Rare Diseases were recognised by EURORDIS (European Organization for Rare Diseases) with an award that was presented to us during the celebration of the 2014 Rare Disease Day.



## RECORDATI RARE DISEASES FONDATION D'ENTREPRISE

We are committed to supporting families affected by these diseases through the distribution of specific scientific knowledge within the medical community.

The Foundation organises training on Rare Diseases to improve diagnosis and spread currently available knowledge on therapeutic options.

The organisation promotes scientific sharing of experience and knowledge between centre of expertise and specialists across the globe.

Every year, the Foundation proposes tailored face to face courses that aim to provide physicians, worldwide, with clinically useful and the most up-to-date information concerning current knowledge and recommendations for care.

The Foundation has delivered over 70 courses to over 3,000 health care professionals since its creation.






## PHARMACEUTICAL CHEMICALS

WE USE A BROAD RANGE OF TECHNOLOGIES TO PRODUCE COMPETITIVELY, MAINTAINING THE HIGHEST QUALITY STANDARDS.

Our pharmaceutical chemicals business focuses on:

- Satisfying the requirements of the pharmaceuticals business.
- Striving for maximum product quality.
- Strengthening our presence in highly regulated markets (the United States, Europe and Japan).
- Safety of production processes.
- Protection of the environment.
- Health and safety in the workplace.

### GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL CHEMICALS SALES IN 2022



**2 DEDICATED SITES**

Campoverde di Aprilia (Italy) and Cork (Ireland)






**A VAST RANGE OF COMPETENCIES**



# 06. PHARMACEUTICAL PRODUCTION

**OUR PRODUCTION SITES ARE EQUIPPED WITH STATE-OF-THE-ART INSTALLATIONS AND OUR RESEARCH LABORATORIES ARE FITTED WITH THE LATEST EQUIPMENT.**

All plants operate in full compliance with environmental protection regulations and in compliance with the cGMP (current Good Manufacturing Practices).

-  Pharmaceutical chemical plants
-  Pharmaceutical manufacturing plants
-  Packaging and distribution center dedicated to products for Rare Diseases

**2 PHARMACEUTICAL CHEMICAL PLANTS**

**7 PHARMACEUTICAL MANUFACTURING PLANTS**

**1 PACKAGING AND DISTRIBUTION CENTRE**  
dedicated to products for Rare Diseases



## PHARMACEUTICAL CHEMICAL PLANTS



### CAMOVERDE DI APRILIA (ITALY)

- This plant is one of the most important producers in the world of verapamil HCl, phenytoin, papaverine HCl, dimenhydrinate, tribenoside and manidipinemanidipine 2HCl.
- In addition to supplying the active ingredients for our proprietary specialties, it is also an established independent producer of active ingredients and intermediates for the pharmaceutical industry internationally.
- The United States is one of the main markets for its production, second only to Europe.
- The site covers a surface of 335,000 sq. m. with a covered area of 35,000 sq. m., it produces approximately 650 MT/year of finished goods.

Approximately 5,000 MT/year of semi-finished goods are handled internally.

- A vast range of competencies in the field of organic synthesis allow us to quickly and effectively study new processes from research right through to final industrialisation.
- The Research and Development laboratories are fitted with an extremely versatile pilot plant equipped for the small-scale production of active ingredients, in accordance with cGMP (current Good Manufacturing Practices).
- Investments have been made to enhance the technological and production capacity of the plant, which – over the last 10 years – has resulted in the installation of 25 new reactors, a latest generation three stage distillation unit for high-temperature





unstable liquids, two thin film evaporators, three filters for the isolation of solid products, three centrifuges and an anti-acid dryer.

- We operate in compliance with current Good Manufacturing Practices (cGMP) and in conformity with the most stringent international environmental regulations. The Plant Environmental Management System is certified according to the UNI EN ISO 14001:2004:2015 by Det Norske Veritas Italia (DNV).

### CORK (IRELAND)

- A dedicated plant built in Cork in Ireland guarantees adequate and continuous supplies of the active ingredient lercanidipine, an important original Recordati drug.

- Automated process control systems ensure constant high-quality and production.
- The site operates in accordance with GMP (Good Manufacturing Practices) and covers a surface area of around 43,000 sq. m., with an installed area of 8,300 sq. m.
- It received the 2012 National Energy Efficiency Award promoted by the sustainable Energy Authority of Ireland (SEAI) and in 2013 received the European Energy Efficiency Award promoted by the Chemical European Federation Industry Council (CEFIC).
- In 2016 the site was extended, the two buildings housing administration and the quality control laboratories were expanded.



## PHARMACEUTICAL MANUFACTURING PLANTS

### ITALY

The Milan site occupies a surface area of around 5,000 sq. m., built vertically over a number of floors for a total of 21,000 sq. m. and produces around 60 million packages per year. It is specialized in the manufacture and packaging of solid oral forms, liquids, and products for topical use.

### FRANCE

The plant at Saint Victor covers a surface of 6,750 sq. m. and produces 29 million packages per year. It is specialized in the production and packaging of liquid, solid oral and spray formulations.

### TÜRKIYE

The site in Çerkezköy, built on 45,000 sq. m. of land, occupies a surface area of approximately 11,300 sq. m. and currently produces 60 million packages per year of solid oral and liquid formulations and products for topical use, of which 27% are dedicated to third party production. The Çerkezköy plant was certified



cGMP (current Good Manufacturing Practices) by the European Union, Azerbaijan, Libya, Kenya, the Russian Federation, Kyrgyzstan and Kazakhstan.

### SPAIN

The Spanish plant is situated near Zaragoza, covering a surface area of 7,100 sq. m. and producing around 22 million packages a year. It is specialised in the production and packaging of solid and liquid oral and topical formulations. In particular, the plant manufactures a line of gastroenterological products. Recently a new line has been installed and approved for the packaging of tablets in bottles which will increase the annual volumes by around eight million packs. In relation to our environmental commitment, the project to install a photovoltaic solar panel system with the capacity to generate up to 185 kWh of electricity for self-consumption has been successfully completed.

### TUNISIA

The site is situated in Ariana, near Tunis. It covers an area of around 9,100 sq. m. and produces around 17 million packages a year of liquid, semi-solid and oral solid forms for the local market and for some of the countries in the





Arabian Peninsula. Certified GMP compliant, the manufacturing site was approved by the Gulf Health Council and the Saudi Food and Drug Authority.

#### SWITZERLAND

The facility, acquired in 2022 through agreements with Novartis for the acquisition of the rights to Signifor®, are located in the north-western part of Switzerland, Basel (within the Novartis Campus).

The plant covers an area of approx. 1,500 sq. m. Since the successful qualification in 2012 and GMP certification by Swissmedic, it is used for commercial production of Signifor® LAR Bulk – a specialised drug product used for the treatment of Acromegaly and Cushing's disease.

#### CZECH REPUBLIC

The plant, situated in Pardubice, produces creams, gels and ointments for a total of two million packages per year, some of which are for third parties.




#### PACKAGING AND DISTRIBUTION CENTRE DEDICATED TO PRODUCTS FOR RARE DISEASES

A new distribution site in Paris exclusively dedicated to products for the treatment of Rare Diseases. It occupies a surface area of 1,600 sq. m. and is entirely dedicated to the packaging, storage and shipping of Rare Disease products. An area of 400 sq. m. is office space.

The site delivers, upon short notice, more than 27,000 orders annually to more than 60 countries worldwide thanks to its highly-qualified staff and a modern GMP (Good Manufacturing Practices) certified logistics platform.



# COMMITMENT, RIGOUR, CAPABILITY





## 07. RESEARCH AND INNOVATION AT RECORDATI

WE CONTINUOUSLY DEVELOP NEW SPECIALTIES ORIGINATING EITHER INTERNALLY OR ACQUIRED THROUGH DEVELOPMENT AGREEMENTS WITH OTHER PHARMACEUTICAL COMPANIES AND RESEARCH INSTITUTES.

Commitment, scientific rigour, capability and highly-specialized personnel allow us to develop new treatments and build an innovative product pipeline.



### INVESTMENT

**220.1** Million Euros

in research and development in 2022  
(includes depreciation relating to the purchase of new products)



### INVESTMENT

**+32.5%**

in research and development  
compared to 2021



## PRODUCT DEVELOPMENT PIPELINE

NAME	ORIGINATOR	INDICATION	DEVELOPMENT STATUS
<b>SIGNIFOR®</b>	Novartis	Pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia	Phase II in progress
<b>REC 0559</b>	Recordati/MimeTech	Neurotrophic keratitis	Phase II in progress
<b>ELIGARD®</b>	Tolmar	Hormone-dependent prostate cancer	New device post-approval activities
<b>ISTURISA®</b>	Novartis	Endogenous Cushing's syndrome Cushing's disease	Approved in the USA, EU, Switzerland, Australia, Israel and Japan. Filed in other countries
<b>QARZIBA®</b>	Apeiron/Recordati	Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutic induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma	Approved in the EU, UK, Australia, Brazil, China Hong Kong, Israel, Russia and Taiwan. Under development for registration in other territories, including USA and Switzerland
<b>SYLVANT®</b>	Recordati	Treatment of idiopathic Multicentric Castleman Disease (iMCD)	Approved in over 40 countries including EU, USA and China. Potential indication expansion evaluation ongoing
<b>REC 0545</b>	Recordati/AP-HP	Acute decompensation episodes in Maple Syrup Urine Disease (MSUD) or leucinosis	EMA MAA (Marketing Authorisation Applications) under evaluation
<b>CYSTADROPS®</b>	Recordati	Corneal cystine crystal deposits in patients with Cystinosis	Approved in the USA and Europe. Development of new formulations in the USA and EU
<b>REAGILA®</b>	Gedeon Richter	Schizophrenia	Pediatric post-approval development plan







# AN IDEAL PARTNER

## 08. PARTNERING WITH THE RECORDATI GROUP

**THANKS TO OUR ABILITY TO DEVELOP SUCCESSFUL RELATIONSHIPS, WE HAVE IMPLEMENTED A STRATEGY OF PARTNERING WITH COMPANIES WITH HIGH STANDARDS IN THE PHARMACEUTICAL SEGMENT.**

We are a partner of choice due to our unique structure, bringing treatment options across Specialty & Primary Care, consumer healthcare, and Rare Diseases.

We have fully-integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.

### STRONG CAPABILITIES & GLOBAL REACH

- Fully integrated company with successful track record in developing, registering, manufacturing and commercialising medicinal products.
- Global footprint with direct presence in more than 50 countries and partnerships in remaining markets.

We have a strong track record in generating value through partnerships with other pharmaceutical companies, whether they are local or global players.

We are committed to generating further growth through mutually-beneficial R&D collaborations, licence agreements and acquisitions.

### FOCUS

- A “local brilliance” commercial approach to each and every market, ensuring growth opportunities are maximised.
- Growth driven by focus on few strategic products that add value to patients, payers and physicians.
- We treat each partnered product as if it were our own.

### BUSINESS DEVELOPMENT TRACK RECORD

- Creative and flexible deal structures to share value with partners.
- Long-lasting strategic partnerships.
- More than 35 transactions completed in the last 15 years.





# OUR BUSINESS DEVELOPMENT STRATEGY

WE ARE LOOKING FOR IN-LICENSING AND ACQUISITION OPPORTUNITIES AND TECHNOLOGIES TO STRENGTHEN OUR PIPELINE AND PORTFOLIO AND FOSTER INNOVATION IN THE FOLLOWING AREAS:



## RARE DISEASES

Innovative products from Clinical Proof of Concept programmes to marketed products, in all therapeutic areas and with a particular focus on:

- Rare endocrinology.
- Rare metabolism.
- Rare oncology.

## SPECIALTY & PRIMARY CARE

Innovative products from Phase 2b clinical stage to marketed products in:

- Cardio-metabolism.
- Urology/ uro-oncology.
- Gastrointestinal.

Established and marketed products across any therapeutic area.

## CONSUMER HEALTHCARE

Well established and marketed CHC products mainly in categories such as:

- Digestive health.
- Women's health & intimate care.
- Respiratory health.



## SELECTED PARTNERSHIPS

LICENSOR	TRADEMARK	THERAPEUTIC AREA	RIGHTS FOR
	Eligard®	Uro-Oncology	Europe & other selected countries
	Qarziba®	Rare oncology	Worldwide
	Fotivda®	Rare oncology	Europe, Latin America, Africa, Australia and New Zealand
	Vitaros®/Virirec®	Urology	Selected European Countries and Africa Portuguese-speaking countries
	Reagila®	CNS	Western Europe, Türkiye and selected countries in Africa
	Ledaga®	Onco-dermatology	Worldwide excluding the USA, Israel, China and other Asian countries
	Urorec®/Silodyx™/ Silosin®	Urology	Europe & other selected countries
	Livazo®/Alipza®	Cardiometabolism	Europe excluding UK and Germany
	Fortacin™	Urology	EU, UK and other selected countries
	Reselip®	Cardiometabolism	France
	Peptazol®	Gastrointestinal	Italy
	Juxtapid®	Rare metabolism	Japan
	Rizmoic®	Gastrointestinal	Spain, Portugal





# SUSTAINABLE AND RESPONSIBLE GROWTH



## APPROXIMATELY 84%

purchased electricity from renewable sources for the Group's plants and annexed offices



## SOLAR PANELS INSTALLED

at production plants in Ireland and Spain



## APPROXIMATELY 7,500 TREES PLANTED

in 2021 and 2022, in the metropolitan area of Milan through the Forestami project, with a commitment to plant 11,250 trees by 2023



## APPROXIMATELY 900

patients affected by Rare Diseases supported through the Patient Assistance Program, the Co-Pay Assistance Program and similar programs



## 11<sup>TH</sup> ARRIGO RECORDATI PRIZE

international award that aims to promote scientific research. The 2024 edition is dedicated to the promotion and recognition of excellence in research on pediatric oncology, specifically neuroblastoma



## € 5.8 MILLION

in donations to the community, € 3.4 million of which was in support of Ukraine (including monetary and product donations measured at market value)



## 1<sup>ST</sup> DIVERSITY & INCLUSION SURVEY COMPLETED

involving approximately 300 Group managers



## 96%

of employees hired on permanent contracts




## 54%

women hired in 2022 out of total new hires, with the commitment to gradually increase the percentage of women in Top and Senior management positions



## 50

suppliers audited on ESG topics via desk audits conducted by an independent third party (EcoVadis)



## OVER 180

supplier audits conducted by the pharmaceutical and chemical-pharmaceutical division, mainly on product quality and safety



# 09. SUSTAINABILITY

## THE VALUES THAT HAVE ALWAYS INSPIRED AND GUIDED US.

We have a long history of entrepreneurial passion, a strong reputation and a desire to continue growing and creating value in an ethical, enduring, and sustainable way, all while respecting the laws and regulations that apply in the countries where we operate, protecting people and the environment, and supplying safe, high-quality products.



### MAIN ESG INDICES AND RATINGS

- FTSE4Good** Confirmed in the **FTSE4Good Index Series**
- MSCI ESG RATINGS** Confirmed **A rating** from MSCI ESG Research\*
- ecovadis** Confirmed **Platinum Rating**
- ISS ESG** Upgrade to **C+ Prime status** by ISS ESG
- Moody's ANALYTICS** **Robust ESG Assessment** from Moody's Analytics
- EURONEXT and BORSA ITALIANA** Inclusion in **MIB ESG index** launched by Euronext and Borsa Italiana



\* The use by the Recordati group of any MSCI ESG Research LLC or its affiliates ("MSCI") data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of Recordati Group by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided 'as-is' and without warranty. MSCI names and logos are trademarks or service marks of MSCI.

# THE SUSTAINABILITY PLAN

The Sustainability Plan is the tool used to share our future trajectory with our stakeholders: it represents an expression of the ambitions of our group and the commitments we wish to prioritise in order to promote sustainable and responsible growth.

### THE 5 ESG STRATEGIC PILLARS

#### PATIENT CARE

Our ambition

We are open to partnering and dedicated to discovering and developing innovative, value-added products that improve quality of life and help people to enjoy longer, healthier and more productive lives.

We wish to offer our patients fast, widespread and sustainable access to our products.

#### PEOPLE CARE

Our ambition

We are committed to creating a safe and inclusive working environment where everyone can express their talents. Our employees are our most important asset and, therefore, we recognise and value the role that each person plays in the success of our business.

We aim to create shared value and positively contribute to sustainable development where we operate, aware of the importance of dialogue, collaboration and respect for the community.

#### ENVIRONMENTAL PROTECTION

Our ambition

Improving human health is the cornerstone of our mission, but we are aware that the health and well-being of present and future generations and the health of our planet are closely interlinked.

With this in mind, we want to take conscious action by working to preserve natural resources and biodiversity and contribute to the fight against climate change by minimising our environmental impact.

#### RESPONSIBLE SOURCING

Our ambition

We want to build relationships based on transparency and trust, sharing our values with suppliers and strategic partners.

We are committed to constantly promoting respect for ethical, environmental and social aspects along the entire value chain.

### ETHICS AND INTEGRITY

Integrity is our founding value, and we lead by example. The principles of honesty and transparency towards our Shareholders and stakeholders guide our daily actions.







## SUPPORT FOR LOCAL COMMUNITIES

We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative.

 **€ 5.8** million in 2022 in donations to the community, € 3.4 million of which was in support of Ukraine (including monetary and product donations measured at market value)

 **7,500** approximately planted trees in 2021 and 2022 in the metropolitan area of Milan through the Forestami project with a commitment to plant 11,250 trees by 2023



## THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI

Established in the year 2000 in memory of Arrigo Recordati, the Prize is an international award which aims to promote scientific research:

The 2024 edition is dedicated to the promotion and recognition of excellence in research on pediatric oncology, specifically neuroblastoma.

- An award of € 100,000 is granted to a scientist in recognition for outstanding work in an innovative research project.
- The winner is chosen by a Jury composed of experts with high international standing.



Sabrina Chiloire, the winner of the X edition, Andrea Recordati and the Jury - Milan 2022 the 23<sup>rd</sup> May





# GROUP LEGAL ENTITIES AND OFFICES

## ITALY

**RECORDATI S.P.A.**  
**INNOVA PHARMA S.P.A.**  
**ITALCHIMICI S.P.A.**  
**NATURAL POINT S.R.L.**  
**RECORDATI RARE DISEASES ITALY S.R.L.**

Headquarter and Registered Office:  
 Via M. Civitali, 1  
 20148 Milan (Italy)  
 Ph. +39 02 48787.1  
 www.recordati.com

Operational Office:  
 Via Roncaglia, 12  
 20146 Milan (Italy)

Specialty & Primary Care:  
 Ph. +39 02 48787.1

Rare Diseases:  
 Ph. +39 02 48787.173

Pharmaceutical  
 Manufacturing Plant:  
 Via M. Civitali, 1  
 20148 Milan (Italy)  
 Ph. +39 02 48787.1

Pharmaceutical Chemical Plant:  
 Via Mediana Cisterna, 4  
 04011 Campoverde di Aprilia, LT (Italy)  
 Ph. +39 06 92900010

## AUSTRALIA

**RECORDATI RARE DISEASES AUSTRALIA PTY LTD.**

Registered Office:  
 Suite 1802, Level 18, 233 Castlereagh Street  
 NSW 2000 Sydney (Australia)  
 Ph. +61 (0) 408 061403  
 Email:  
 RRDAustraliainfo@recordati.com

## AUSTRIA

**RECORDATI AUSTRIA GMBH**

Registered Office:  
 c/o Next Pharma Logistiscs  
 Julius Raab-Straße 26, A-2203  
 Großbeersdorf (Austria)  
 Ph: +43 2279 51018-0

## BENELUX

**RECORDATI BV / S.R.L**

Registered Office:  
 Avenue du Bourgmeestre Demunter,  
 5 Boite 4  
 1090 Jette (Belgium)  
 Ph.: +32 2 461.01.36  
 Email: infobenelux@recordati.com

**RECORDATI NETHERLANDS B.V.**

Registered Office:  
 Beechavenue, 54  
 1119PW Schiphol-Rijk (Netherlands)

## BRAZIL

**RECORDATI RARE DISEASES COMÉRCIO DE MEDICAMENTOS LTDA**

Registered Office:  
 Barueri-SP, na Avenida Piraiba, 296,  
 sala 9 – Parte B  
 Centro Comercial Jubran,  
 CEP 06460-121 (Brazil)

Branch Registered Office:  
 Cidade de São Paulo, estado de  
 São Paulo na Rua Surubim, nº 504,  
 conjunto 31  
 Edifício Berrini Park, Cidade  
 Monções, CEP 04571-050 (Brazil)

## BULGARIA

**RECORDATI BULGARIA LTD.**

Registered Office:  
 84 "Al. Stamboliiski" Blvd.  
 Floor 8, Office No. 44  
 1303 Sofia (Bulgaria)  
 Ph. +359 2 829 39 37  
 Email: Penkova.d@recordati.com

Trade Representation Office:  
 84, "Al. Stamboliyski" Blvd.  
 Floor 8, Office No. 44  
 1303 Sofia (Bulgaria)

## CANADA

**RECORDATI RARE DISEASES CANADA INC.**

Registered Office:  
 333 Bay Street, Suite 2400  
 M5H 2T6 Toronto, ON (Canada)  
 Email: infocanada@recordati.com

Operational Office:  
 3080 Yonge Street, Suite 6060  
 M4N 3N1 Toronto, ON (Canada)

## CHINA

**RECORDATI (BEIJING) PHARMACEUTICAL CO., LTD.**

Registered Office:  
 Unit 03, 05, 1T01, Office 26, 26th  
 Floor, No. 81, Jianguo Road  
 Chaoyang District, Beijing (China)

## COLOMBIA

**RECORDATI RARE DISEASES COLOMBIA S.A.S**

Registered Office:  
 Carrera 7 N° 127, 48 Oficina 1202,  
 Edificio 128, Centro Empresarial  
 Bogotá D.C. (Colombia)  
 Ph. +57 1 6472780  
 Email:  
 RRDColombiainfo@recordati.com

## CZECH REPUBLIC AND SLOVAKIA

**HERBACOS RECORDATI S.R.O.**

Registered Office:  
 Štrossova 239, 530 03  
 Pardubice (Czech Republic)  
 Ph. +420 227 200 722  
 Email: recordati@recordati.cz

**RECORDATI SK S.R.O**

Registered Office:  
 Vavrinská 5  
 831 52 Bratislava (Slovakia)

Pharmaceutical  
 Manufacturing Plant:  
 Štrossova 239  
 530 03 Pardubice (Czech Republic)  
 Ph. +420 466 614 055  
 Email: recordati@recordati.cz

## DENMARK

**EUSA PHARMA (DENMARK) APS**

Registered Office:  
 c/o Crowe Horwath  
 Rygårds Allé 104  
 2900 Hellerup (Denmark)  
 Ph.+ 44 (0) 3305001210

## FRANCE

**BOUCHARA-RECORDATI S.A.S FIC MÉDICAL SARL (with representative offices in several C.I.S. countries)**

**LABORATOIRES BOUCHARA RECORDATI S.A.S**

**RECORDATI RARE DISEASES S.A.R.L**

**TONIPHARM S.A.S**  
 Registered Office:  
 Immeuble "Le Wilson"  
 70, avenue du Général De Gaulle  
 92800 Puteaux (France)  
 Ph. +33 1 45191000  
 Email:  
 RRDFranceinfo@recordati.com

Pharmaceutical  
 Manufacturing Plant:  
 Parc Mécatronic  
 03410 Saint Victor (France)  
 Ph. +33 4 70037900

Packaging and Distribution Center  
 (dedicated to products for rare  
 diseases):  
 Eco River Parc, 30 Rue des Peupliers  
 92752 Nanterre (France)  
 Ph. +33 1 70 82 44 31

## GERMANY

**RECORDATI PHARMA GMBH**

Registered Office:  
 Eberhard-Finckh-Str. 55  
 89075 Ulm (Germany)  
 Ph. +49 731 7047.0

## RECORDATI RARE DISEASES GERMANY GMBH

Registered Office:  
 Eberhard-Finckh-Str. 55  
 89075 Ulm (Germany)  
 Ph. +49 731 140 554 0  
 Email:  
 RRDGermanyinfo@recordati.com

## GREECE

**RECORDATI HELLAS PHARMACEUTICALS S.A.**

Registered Office:  
 7, Zoodochou Pigis Str.  
 15231 K. Chalandri  
 Atene (Greece)  
 Ph. +30 210 6773822

## IRELAND

**RECORDATI IRELAND LTD.**

Registered Office:  
 Raheens East  
 Ringaskiddy, Co. Cork  
 P43 KD30 (Ireland)  
 Ph. +353 21 437 94 00

## JAPAN

**RECORDATI RARE DISEASES JAPAN K.K.**

Registered Office:  
 1-10-2, Ichibancho, Chiyoda-ku  
 102-0082 Tokyo (Japan)  
 Ph. +81 3 4510 2910  
 Email: RRDJapaninfo@recordati.com

## KOREA

**RECORDATI KOREA, CO., LTD.**

Registered Office:  
 DongHee Building, 4th Fl. 302  
 Gangnamdae-ro, Gangnam-gu  
 06236 Seoul (Korea)

## MALAYSIA

**RECORDATI RARE DISEASES S.A.R.L.**

Registered Office:  
 c/o CCFM Incubator  
 Unit 25-9, 25th Floor  
 Menara 1MK  
 No 1, Jalan Kiara, Mont Kiara, 50480  
 Kuala Lumpur (Malaysia)

## MIDDLE EAST

**RECORDATI RARE DISEASES MIDDLE EAST FZ-LLC**

Registered Office:  
 Dubai Healthcare City  
 Building 25, Unit 205-206, P.O. Box  
 505075  
 Dubai (UAE)  
 Ph. +971 4 363 5454  
 Email:  
 RRDMiddleeastinfo@recordati.com



## RECORDATI RARE DISEASES FZCO

Registered Office:  
 Building 8E, Office 402, DAFZA, P.O.  
 Box: 505075  
 Dubai (UAE)

## MEXICO

**RECORDATI RARE DISEASES S.A. DE C.V.**

Registered Office:  
 Avenida Ejercito Nacional 418-307  
 Col. Polanco V Sección  
 11560 Miguel Hidalgo, Ciudad de  
 México (Mexico)  
 Email:  
 RRDMexicoinfo@recordati.com

Operational Office:  
 IZA Torre Prisma  
 Av. Insurgentes Sur 1647 Floor 4  
 Office 421  
 Col. San José Insurgentes  
 03900 Delegación Benito Juárez,  
 Ciudad de México (Mexico)  
 Ph. +525526140975

## POLSKA

**RECORDATI POLSKA SP. Z O.O.**

Registered Office:  
 al. Armii Ludowej 26  
 00-609 Warsaw (Polska)  
 Ph. +48 22 206 84 50

## PORTUGAL

**JABA RECORDATI S.A.**  
**CASEN RECORDATI PORTUGAL UNIPessoal L.D.A.**

**BONAFARMA - PRODUTOS FARMACÉUTICOS S.A.**

**JABAFARMA - PRODUTOS FARMACÉUTICOS S.A.**

Registered Office:  
 Av. Jacques Delors  
 Ed. Inovação 1.2, Piso 0 - Taguspark  
 2740-122 Porto Salvo (Portugal)  
 Ph. +351 21 4329.500

**EUSA PHARMA (UK) LTD. - SUCURSAL EM PORTUGAL**

Registered Office:  
 Rua Braamcamp, n. 6 – 1º Esq.  
 Lisboa (Portugal)  
 Ph.+351 (0) 308801554

## ROMANIA

**RECORDATI ROMANIA S.R.L.**

Registered Office:  
 92-96 Izvor street,  
 Office B, 4th floor, Rooms 2-8,5th  
 District  
 Bucarest (Romania)  
 Ph. +40 21 667 17 41 - 2

## RUSSIA AND C.I.S.

**RUSFIC LLC**  
**OOO ACCENT LTD.**

Registered Office:  
 Krasnopresnenskaya Naberezhnaya  
 12  
 Entrance 7, floor 6, premises 2  
 123610, Moscow (Russian  
 Federation)  
 Email: info@rusfic.com  
 Email: RRDRussiainfo@recordati.com

## SPAIN

**CASEN RECORDATI S.L.**

Registered Office:  
 Autovia de Logroño, km. 13,300  
 50180 Utebo, Zaragoza (Spain)

Operational Office:  
 Via de las Dos Castillas, 33 - 3º planta  
 Ática, Edificio 7  
 28224 Pozuelo de Alarcón, Madrid  
 (Spain)  
 Ph. + 34 91 351 88 00  
 Ph. + 34 91 659 15 50

Pharmaceutical  
 Manufacturing Plant:  
 Autovia de Logroño, km. 13,300  
 50180 Utebo, Zaragoza (Spain)  
 Ph. + 34 97 646 26 26

**RECORDATI RARE DISEASES SPAIN, S.L.**

Registered Office:  
 Autovia de Logroño, km. 13,300  
 50180 Utebo, Zaragoza (Spain)  
 Ph. + 34 97 646 26 26

Operational Office:  
 Via de las Dos Castillas, 33 - 3º planta  
 Ática, Edificio 7  
 28224 Pozuelo de Alcaron, Madrid  
 (Spain)  
 Ph. + 34 91 351 88 00  
 Ph. + 34 91 659 15 50

## SWEDEN

**RECORDATI AB.**

Registered Office:  
 Jan Stenbecks Torg 17, 2 tr  
 16440 Kista (Sweden)  
 Ph. +46 8 545 80 230  
 Email: InfoNordic@recordati.com

## SWITZERLAND

**RECORDATI AG**

Registered Office:  
 Lindenstrasse, 8  
 6340 Baar (Switzerland)  
 Ph. +41 41 769.1000  
 Email: info@recordati.ch

## RECORDATI AG, RARE DISEASES BRANCH

Registered Office:  
 Uferstrasse, 90  
 4057 Basel (Switzerland)  
 Ph. + 41 61 205 61 00  
 Email:  
 info.rarediseases.ch@recordati.com

Pharmaceutical  
 Manufacturing Plant:  
 Lindenstrasse, 8  
 6340 Baar (Switzerland)  
 Ph. +41 41 769.1000

**EUSA PHARMA (CH) GMBH**

Registered Office:  
 C/O Curator & Horwath AG  
 Zweigniederlassung Zug  
 Industriestrasse 7  
 6300 Zug (Switzerland)  
 Ph. +41 (0) 800001415

## TUNISIA

**OPALIA RECORDATI S.A.R.L.**

Registered Office:  
 27 Avenue De La Livre Sterling  
 Les Berges du Lac 2  
 1053 Tunis (Tunisia)  
 Ph. +216 70 559 070-064  
 Email:  
 communication@opalia.com.tn

**OPALIA PHARMA S.A.**

Registered Office  
 and Pharmaceutical  
 Manufacturing Plant:  
 Zone Industrielle de Kalaat El  
 Andalous, Lot 3 à 8 - 2022 Ariana  
 (Tunisia)

## TÜRKIYE

**RECORDATI İLAÇ SANAYİ VE TİCARET A.S.**

Registered Office  
 and Manufacturing Plant:  
 Çerkezköy Organize Sanayi Bölgesi  
 Karaağaç Mahallesi Atatürk  
 Caddesi No:36 Kapaklı  
 59510 Tekirdağ İstanbul (Türkiye)

Administrative Office:  
 Maslak Mah. Sümer Sok. No: 4  
 Maslak Office Building  
 İstanbul (Türkiye)  
 Ph. +90 212 401 91 00

Pharmaceutical  
 Manufacturing Plant:  
 Çerkezköy Organize Sanayi Bölgesi  
 Karaağaç Mahallesi Atatürk  
 Caddesi No:36 Kapaklı  
 59510 Tekirdağ İstanbul (Türkiye)  
 Ph. +90 282 999 16 00

**RECOFARMA İLAÇ VE HAMMADELERİ SANAYİ VE TİCARET LİMİTED ŞİRKETİ**

Maslak Mahallesi Sümer Sk. Kar Plaza  
 Apt. No: 4/21  
 Sarıyer/İstanbul (Türkiye)

## UKRAINE

**RECORDATI UKRAINE LLC**

Registered Office:  
 40, Hlybochyska Str.  
 04050 Kyiv (Ukraine)  
 Ph. +380 44 351 18 63

## UNITED KINGDOM

**RECORDATI PHARMACEUTICALS LTD.**

Registered Office:  
 Breakspear Park  
 Hemel Hempstead HP2 4TZ  
 (United Kingdom)  
 Ph. +44 1 49 1576 336  
 Email:  
 customerservice@recordati.com

**EUSA PHARMA (UK) LTD.**

Registered Office:  
 Breakspear Park  
 Hemel Hempstead HP2 4TZ  
 (United Kingdom)  
 Ph.+44 (0) 330 500 1140

**RECORDATI RARE DISEASES UK LTD.**

Registered Office:  
 Greengarth, Thicket Grove,  
 Maidenhead  
 Berkshire, SL6 4LW (United Kingdom)  
 Email: infoRRDUK@recordati.com

**Operational Office:**

Breakspear Park  
 Hemel Hempstead HP2 4TZ  
 (United Kingdom)  
 Ph. +44 1 49 1576 336  
 Email:  
 customerservice@recordati.co.uk

## UNITED STATES

**RECORDATI RARE DISEASES INC.**

Registered Office:  
 c/o the Prentice – Hall Corporation  
 System, Inc., 2711 Centerville Road,  
 Suite 400, Wilmington, County of  
 New Castle  
 19801 Delaware (USA)  
 Email:  
 info@recordatirarediseases.com

**Operational Office:**  
 440 Rte 22 E, Suite 205  
 Bridgewater  
 08807 New Jersey (USA)





The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group's activities and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising. iStock images are included for illustrative purposes only.

Produced by Recordati S.p.A. Concept and graphic design by TATOMMI  
Photography: Archivio Recordati, Riccardo Sarri, iStock  
iStock images are included for illustrative purposes only

November 2023